Did you know that antibiotic resistance is one of the biggest public health threats of our time? And
yet it is often overlooked by healthcare companies and investors. Hi, I am Camille Rigaud from Kieger.
Every year, approximately 700,000 people die from antibiotic resistance and, by 2050, this number
could reach 10 million if no action is taken according to the UN. Without effective antibiotics to treat or prevent infections, common surgical procedures such as a hip replacement or a C-section, for example, could become too risky to perform. The antibiotic arsenal has been dwindling, with the number of new antibiotics approved in the US declining, as it has also elsewhere in the world.
Large pharma companies have left this business due to unattractive economics and small biotech
firms have been trying to fill the gap. However, many struggle to get funding and many have filed for
bankruptcy or were sold off.
We need more industry commitments as well as new incentive mechanisms to drive the development
of novel and effective antibiotics. Covid is a reminder of the threat of new infectious diseases and that the world needs to be better prepared for the next threat.
We attended the ASCO 2023 annual meeting in Chicago. After the rise of immuno-oncology, COVID-19 challenged clinical trial execution and muted patient numbers. In the last years we saw many setbacks of once promising immuno-oncology combinations trials.
What mattered this month in healthcare? Q1 reporting came to a close, and FTC action put pressure on the biopharma space and... Find out more in our monthly healthcare newsletter.
With M&A picking up, are we at a turning point for biotech? Check out our latest Kieger AG Chart of the Month Video.